Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Automatically detect candlestick patterns on any chart

Read How
Market News Market Pulse Stocks News ETF News Crypto News

NewAmsterdam Pharma N.V.

Contributing Author

Recent Articles by NewAmsterdam Pharma N.V.

Aug-26
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 NAMS GlobeNewswire
Aug-06
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAMS GlobeNewswire
Aug-05
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results NAMS GlobeNewswire
Jul-29
NewAmsterdam Pharma to Host Investor Day on August 5, 2026 NAMS GlobeNewswire
Jul-24
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) NAMS GlobeNewswire
Jul-02
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAMS GlobeNewswire
Jul-01
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026 NAMS GlobeNewswire
Jun-03
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions NAMS GlobeNewswire
May-28
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June NAMS GlobeNewswire
May-11
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May NAMS GlobeNewswire
May-07
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results NAMS +12.46% GlobeNewswire
May-01
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAMS NAMS +5.03% GlobeNewswire
Apr-08
NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference NAMS GlobeNewswire
Apr-02
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAMS GlobeNewswire
Mar-23
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session NAMS GlobeNewswire
Mar-06
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAMS GlobeNewswire
Feb-25
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March NAMS GlobeNewswire
Feb-18
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update NAMS GlobeNewswire
Feb-06
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAMS +6.99% GlobeNewswire
Feb-04
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit NAMS GlobeNewswire
Jan-09
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities NAMS GlobeNewswire
Jan-05
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAMS GlobeNewswire
Dec-05
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAMS GlobeNewswire
Nov-25
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December NAMS GlobeNewswire
Nov-07
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAMS NAMS +6.01% GlobeNewswire
Nov-05
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results NAMS GlobeNewswire
Oct-30
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November NAMS +8.05% GlobeNewswire
Sep-24
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum NAMS GlobeNewswire
Aug-25
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September NAMS GlobeNewswire
Aug-18
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib NAMS GlobeNewswire
Aug-06
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results NAMS +8.70% GlobeNewswire
Jul-30
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025 NAMS GlobeNewswire
Jul-22
NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025 NAMS GlobeNewswire
Jun-09
NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial NAMS GlobeNewswire
Jun-05
NewAmsterdam Pharma to Host R&D Day on June 11, 2025 NAMS GlobeNewswire
May-27
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June NAMS GlobeNewswire
May-14
NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference NAMS GlobeNewswire
May-08
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results NAMS GlobeNewswire
May-07
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025 NAMS GlobeNewswire
May-02
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAMS GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)